Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.

Baruch A, Luca D, Kahn RS, Cowan KJ, Leabman M, Budha NR, Chiu CPC, Wu Y, Kirchhofer D, Peterson A, Davis JC Jr, Tingley WG.

Clin Cardiol. 2017 Jul;40(7):503-511. doi: 10.1002/clc.22687. Epub 2017 Mar 22.

2.

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M, Iyer S.

MAbs. 2016;8(3):593-603. doi: 10.1080/19420862.2015.1136043. Epub 2016 Feb 26.

3.

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.

Budha NR, Leabman M, Jin JY, Wada DR, Baruch A, Peng K, Tingley WG, Davis JD.

AAPS J. 2015 Jul;17(4):881-90. doi: 10.1208/s12248-015-9750-8. Epub 2015 Mar 31.

4.

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.

Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK.

MAbs. 2014;6(6):1500-8. doi: 10.4161/mabs.36208.

5.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.

Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.

6.

Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.

Gelzleichter TR, Halpern W, Erwin R, Baruch A, Leabman M, Forrest AS, Satterwhite CM, Peng K, Chilton J, Stevens D.

Toxicol Sci. 2014 Aug 1;140(2):470-80. doi: 10.1093/toxsci/kfu093. Epub 2014 May 20.

PMID:
24848798
7.

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S.

MAbs. 2013 Nov-Dec;5(6):896-903. doi: 10.4161/mabs.26436.

8.

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J.

Sci Transl Med. 2011 Dec 14;3(113):113ra126. doi: 10.1126/scitranslmed.3002669.

9.

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB.

J Immunol. 2009 Jun 15;182(12):7663-71. doi: 10.4049/jimmunol.0804182.

10.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

11.

Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.

Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G, Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE, Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, Martin F.

Blood. 2007 Dec 1;110(12):3959-67. Epub 2007 Aug 8.

12.

PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters.

Shu Y, Urban TJ, Leabman MK, Fujita T, Erdman AR, Lagpacan LL, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Taylor TR, Chan W, De La Cruz M, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Herskowitz I, Kroetz DL, Giacomini KM.

Pharmacol Rev. 2006 Mar;58(1):3-4. No abstract available.

PMID:
16507878
13.

Functional genomics of membrane transporters in human populations.

Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL, Risch N, Giacomini KM.

Genome Res. 2006 Feb;16(2):223-30. Epub 2005 Dec 14.

14.

Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.

Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM.

J Pharm Sci. 2006 Jan;95(1):25-36. Review.

PMID:
16307453
15.

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).

Fujita T, Brown C, Carlson EJ, Taylor T, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Fujita K, Castro R, Chen CW, Lin ET, Brett CM, Burchard EG, Ferrin TE, Huang CC, Leabman MK, Giacomini KM.

Pharmacogenet Genomics. 2005 Apr;15(4):201-9.

PMID:
15864112
16.

PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1.

Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM.

Pharmacol Rev. 2004 Jun;56(2):161. No abstract available.

PMID:
15169925
17.

Estimating the contribution of genes and environment to variation in renal drug clearance.

Leabman MK, Giacomini KM.

Pharmacogenetics. 2003 Sep;13(9):581-4.

PMID:
12972957
18.

PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2).

Leabman MK, Huang CC, Stryke D, Johns SJ, Kawamoto M, Ferrin TE, DeYoung J, Taylor TR, De La Cruz M, Herskowitz I, Giacomini KM.

Pharmacol Rev. 2003 Sep;55(3):399. Epub 2003 Jul 17. Review. No abstract available.

PMID:
12869664
19.

Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.

Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM; Pharmacogenetics Of Membrane Transporters Investigators.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5902-7. Epub 2003 Apr 28.

20.

Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.

Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz DL, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM; Pharmacogenetics Of Membrane Transporters Investigators.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5896-901. Epub 2003 Apr 28.

21.

SNP analysis and presentation in the Pharmacogenetics of Membrane Transporters Project.

Stryke D, Huang CC, Kawamoto M, Johns SJ, Carlson EJ, Deyoung JA, Leabman MK, Herskowitz I, Giacomini KM, Ferrin TE.

Pac Symp Biocomput. 2003:535-47.

22.

Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2).

Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM.

Pharm Res. 2002 Aug;19(8):1244-7. No abstract available.

PMID:
12240953
23.

Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, Giacomini KM; Pharmacogenetics of Membrane Transporters Investigators.

Pharmacogenetics. 2002 Jul;12(5):395-405.

PMID:
12142729
24.

Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters.

Dresser MJ, Leabman MK, Giacomini KM.

J Pharm Sci. 2001 Apr;90(4):397-421. Review.

PMID:
11170032

Supplemental Content

Loading ...
Support Center